Efegatran sulfate
| Code | Size | Price |
|---|
| TAR-T25364L-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25364L-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25364L-5mg | 5mg | £1,034.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Efegatran sulfate is an antithrombotic agent.
CAS:
126721-07-1
Formula:
C21H34N6O7S
Molecular Weight:
514.6
Purity:
0.98
SMILES:
OS(O)(=O)=O.CN([C@@H](CCCNC(N)=N)C=O)[C@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(N)=O
References
1. Fung AY, Lorch G, Cambier PA, Hansen D, Titus BG, Martin JS, Lee JJ, Every NR, Hallstrom AP, Stock-Novack D, Scherer J, Weaver WD. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Am Heart J. 1999 Oct;138(4 Pt 1):696-704. PubMed PMID: 10502216.
2. PRIME Investigators. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am Heart J. 2002 Jan;143(1):95-105. PubMed PMID: 11773918.
3. Lijnen HR. Efegatran. Institute for drug research/IVAX. IDrugs. 2001 Jun;4(6):691-4. PubMed PMID: 16001314.
4. Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, M?ller EJ, Poortermans KJ, Deckers JW, Simoons ML. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J. 1999 Aug;20(15):1101-11. PubMed PMID: 10413640.